In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...
Zimbabwe introduces lenacapavir, a new HIV prevention drug administered twice a year, offering hope for high-risk groups but ...
Within five years, the researchers believe blood tests for early diagnosis of Parkinson’s disease could begin to be tested in healthcare settings. Over the longer term, the findings may also support ...
A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...
WASHINGTON (AP) — The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies to ...
In a major step forward against Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted ...
The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results